NCT00901836终止不适用
A Pilot Study Investigating Preoperative Proton Radiotherapy for Retroperitoneal Sarcoma
适应症
试验速览
- 阶段
- 不适用
- 状态
- 终止
- 入组人数
- 2
- 试验地点
- 2
- 主要终点
- To assess treatment feasibility of preoperative proton therapy for resectable intermediate or high grade retroperitoneal sarcoma.
研究概览
简要总结
The goal of this study is to evaluate radiation treatment intended to increase the chance of curing your sarcoma and decrease the side effects of proton therapy.
This study will also look at the tumor tissue that was removed during your initial biopsy and your final surgery for information that may help to treat retroperitoneal sarcoma in the future.
详细描述
Data collection will be obtained from the patient's medical records including initial evaluation, pathology report, dosimetry information, radiotherapy completion records and follow-up.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •Patients must have histologically-confirmed intermediate or high grade retroperitoneal sarcomas of any histologic subtype.
- •Primary or recurrent disease isolated to a single intra-abdominal or retroperitoneal region is allowed.
- •Tumor must be considered potentially completely resectable as defined by cross sectional imaging (no 360o encasement of the superior mesenteric artery, aorta, inferior vena cava, iliac arteries or iliac veins and no extension of tumor into the vertebral column).
- •At least 2 weeks must have elapsed from any prior surgery or hormonal therapy. Patients must have ≤ grade 1 acute toxicities of any prior treatment with anti-cancer modalities (returned to baseline status as noted before most recent treatment). Patients with persisting, stable chronic toxicities from prior treatment ≤ grade 1 are eligible.
- •Age ≥18 years at time of consent.
- •Life expectancy of greater than 3 months. Physician documented.
- •Women of child-producing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation and the subsequent 6 months. Patients must have a negative serum pregnancy test within 2 weeks prior to beginning treatment on this trial. Sexually active men must also use appropriate contraception method and should not father a child while receiving therapy during this study.
- •Ability to understand and the willingness to sign a written Institutional Review Board(IRB) stamped study specific informed consent document before undergoing research related procedures or study treatment.
- •Biopsy is required with pathologic confirmation of intermediate or high grade sarcoma with pathology review at the University of Florida.
- •Agree to allow their tissue to be used for current study.
排除标准
- •Receiving any investigational agents.
- •Evidence of metastatic disease.
- •Uncontrolled intercurrent illness and/or psychiatric illness/social situations that would limit compliance with study requirements.
- •Pregnant and nursing women are excluded from this study because the radiotherapy may have the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with these agents, breastfeeding should be discontinued if the mother is treated.
- •All herbal and/or alternative medications should be discontinued while on study, including, but not limited to: Hydrastis canadensis (goldenseal), Uncaria tomentosa (cat's claw) or Echinacea angustifolia.
- •Requirement for treatment with immunosuppressive agents or chronic steroids.
- •Previous intra-abdominal or retroperitoneal radiotherapy.
- •Treatment with cytotoxic agents and/or treatment with biologic agents within the 4 weeks prior to beginning treatment on this study.
结局指标
主要结局
To assess treatment feasibility of preoperative proton therapy for resectable intermediate or high grade retroperitoneal sarcoma.
时间窗: 4-6 weeks post treatment
次要结局
- To evaluate the acute and late toxicity of preoperative proton therapy for resectable intermediate or high grade retroperitoneal sarcoma(Weekly during treatment, then every 3 months for 1 year, then every 6 months for 4 years.)
- To determine the percent tumor necrosis and percent apoptosis compared to historic controls treated with photon therapy.(4-6 weeks post treatment)
- To compare the dose distribution to tumor and surrounding normal structures using dose volume histograms (DVHs) generated from the proton plan used to treat the patient and a theoretical photon plan generated for comparison purposes.(4-6 weeks post treatment)
- To assess the predictive value of CT and MRI in evaluating pathologic tumor response and margin negative resection following proton radiotherapy.(4-6 weeks post treatment)
- To determine the incidence of margin negative resection in patients compared to historic controls treated with photon therapy.(4-6 weeks post treatment)
研究者
研究点 (2)
Loading locations...
相似试验
招募中
2 期
Preoperative Radiotherapy and Immunotherapy for Sinonasal and Anorectal Mucosal MelanomaNCT05546827M.D. Anderson Cancer Center40
已完成
不适用
Pre-operative Stereotactic Radiosurgery Followed by Resection for Brain MetastasesMalignant Neoplasm BrainNCT02514915Christopher Wilke24
已完成
1 期
Proton Beam Radiation Therapy and Chemotherapy in Treating Patients With Stage III Non-Small Cell Lung Cancer That Can Be Removed By SurgeryStage IIIA Non-small Cell Lung CancerNCT01076231Abramson Cancer Center at Penn Medicine34
已完成
不适用
Proton Radiation Therapy for Invasive Breast Cancer Following MastectomyInvasive Breast CancerNCT01340495Massachusetts General Hospital70
终止
3 期
Pre- Versus Post-operative SRS for Resectable Brain MetastasesBrain MetastasesNCT04474925AHS Cancer Control Alberta8